| 
                       
                    | 
		
			
                    
                        
                            | 
                               
                             | 
                         
                        
                        
                            | 
                                
                             | 
                            
                                
                             | 
                         
                        
                            | 
                                Plant-based medicines can be harmful
                             | 
                         
                        
                            | 
                             | 
                         
                                                                                      
                        
                    | 
		
			
                    
                        
                            
                               Marketing Authorisations 
                             | 
                         
                        
                        
                            | 
                                
                             | 
                            
                                
                             | 
                         
                        
                            | 
                                Metastatic melanoma: a few extra months of life, but many adverse effects
                             | 
                         
                        
                            | 
                             | 
                         
                                                                                      
                        
                    | 
		
			
                    
                        
                            | 
                               
                             | 
                         
                        
                        
                            | 
                                
                             | 
                            
                                
                             | 
                         
                        
                            | 
                                Metastatic melanoma: a me-too of vemurafenib
                             | 
                         
                        
                            | 
                             | 
                         
                                                                                      
                        
                    | 
		
			
                    
                        
                            | 
                               
                             | 
                         
                        
                        
                            | 
                                
                             | 
                            
                                
                             | 
                         
                        
                            | 
                                Multiple sclerosis: too many long-term unknowns
                             | 
                         
                        
                            | 
                             | 
                         
                                                                                      
                        
                    | 
		
			| 
                       
                    | 
		
			
                    
                        
                            | 
                               
                             | 
                         
                        
                        
                            | 
                                
                             | 
                            
                                
                             | 
                         
                        
                            | 
                                An aggressive topical treatment for anogenital warts
                             | 
                         
                        
                            | 
                             | 
                         
                                                                                      
                        
                    | 
		
			
                    
                        
                            | 
                               
                             | 
                         
                        
                        
                            | 
                                
                             | 
                            
                                
                             | 
                         
                        
                            | 
                                Ready to use, but more serious adverse effects than IV trastuzumab
                             | 
                         
                        
                            | 
                             | 
                         
                                                                                      
                        
                    | 
		
			
                    
                        
                            | 
                               
                             | 
                         
                        
                        
                            | 
                                
                             | 
                            
                                
                             | 
                         
                        
                            | 
                                A controversial EU re-evaluation upholds marketing authorisation, unfortunately
                             | 
                         
                        
                            | 
                             | 
                         
                                                                                      
                        
                    | 
		
			
                    
                        
                            | 
                               
                             | 
                         
                        
                        
                            | 
                                
                             | 
                            
                                
                             | 
                         
                        
                            | 
                                An oral solution of phenobarbital with dangerous packaging
                             | 
                         
                        
                            | 
                             | 
                         
                                                                                      
                        
                    | 
		
			
                    
                        
                            | 
                               
                             | 
                         
                        
                        
                            | 
                                
                             | 
                            
                                
                             | 
                         
                        
                            | 
                                More evaluation needed, in both first- and second-line use
                             | 
                         
                        
                            | 
                             | 
                         
                                                                                      
                        
                    | 
		
			
                    
                        
                            
                               Adverse Effects 
                             | 
                         
                        
                        
                            | 
                                
                             | 
                            
                                
                             | 
                         
                        
                            | 
                                Hypotension and persistent tachycardia
                             | 
                         
                        
                            | 
                             | 
                         
                                                                                      
                        
                    | 
		
			
                    
                        
                            | 
                               
                             | 
                         
                        
                        
                            | 
                                
                             | 
                            
                                
                             | 
                         
                        
                            | 
                                Stop medication as soon as possible
                             | 
                         
                        
                            | 
                             | 
                         
                                                                                      
                        
                    | 
		
			
                    
                        
                            | 
                               
                             | 
                         
                        
                        
                            | 
                                
                             | 
                            
                                
                             | 
                         
                        
                            | 
                                Miscarriages and major malformations
                             | 
                         
                        
                            | 
                             | 
                         
                                                                                      
                        
                    | 
		
			
                    
                        
                            | 
                               
                             | 
                         
                        
                        
                            | 
                                
                             | 
                            
                                
                             | 
                         
                        
                            | 
                                Unfavourable harm-benefit balance
                             | 
                         
                        
                            | 
                             | 
                         
                                                                                      
                        
                    | 
		
			| 
                       
                    | 
		
			
                    
                        
                            
                               Reviews 
                             | 
                         
                        
                        
                            | 
                                
                             | 
                            
                                
                             | 
                         
                        
                            | 
                                Non-randomised comparisons: results similar to those of randomised trials
                             | 
                         
                        
                            | 
                             | 
                         
                                                                                      
                        
                    | 
		
			| 
                       
                    | 
		
			
                    
                        
                            | 
                               
                             | 
                         
                        
                        
                            | 
                                
                             | 
                            
                                
                             | 
                         
                        
                            | 
                                Metformin is the only glucose-lowering drug known to prevent complications of diabetes
                             | 
                         
                        
                            | 
                             | 
                         
                                                                                      
                        
                    | 
		
			| 
                       
                    | 
		
			
                    
                        
                            
                               Outlook 
                             | 
                         
                        
                        
                            | 
                                
                             | 
                            
                                
                             | 
                         
                        
                            | 
                                Some advances this year, but many drugs are poorly evaluated, too expensive or more dangerous than useful
                             | 
                         
                        
                            | 
                             | 
                         
                                                                                      
                        
                    | 
		
			
                    
                        
                            | 
                               
                             | 
                         
                        
                        
                            | 
                                
                             | 
                            
                                
                             | 
                         
                        
                            | 
                                Demonstrated impact on prescribing behaviour
                             | 
                         
                        
                            | 
                             | 
                         
                                                                                      
                        
                    |